Share on Pinterest A study offers new clues on why long COVID persists in some individuals. krisanapong detraphiphat/Getty Images Despite the debilitating nature of long COVID, there is an absence of ...

Most people infected with the SARS-CoV-2 virus recover after the acute illness. However, a significant proportion of infected individuals develop long-lasting symptoms with a wide range of ...

Changes to serum proteins could be behind the debilitating condition known as long COVID. The findings, published in the journal Science, could pave the way for diagnosing and treating the disease.

Dianthus achieved its NASDAQ listing last year via a merger with Magenta Therapeutics. The company is focused on development of a single drug candidate, DNTH-103, which targets the complement system, ...

Please provide your email address to receive an email when new articles are posted on . A protein known as granzyme K was recently shown to be a driver of inflammation by activating the complement ...

Novo Nordisk is paying $240 million for global rights to a Phase 3-ready drug from Omeros that could rival immune disorder medications currently available from companies such as AstraZeneca, Novartis, ...

Complement 3 glomerulopathy (C3G) and immunoglobulin A nephropathy (IgAN) kidney diseases are progressive glomerular conditions. Their treatments typically involve medications to control inflammation ...

"Patients with active long COVID disease also had elevated blood levels indicating damage to various body cells." Credit: Enrique Heer "Patients with active long COVID disease also had elevated blood ...